{"id":"lipiodol-ultrafluid","safety":{"commonSideEffects":[{"rate":null,"effect":"Transient fever"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hepatic dysfunction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lipiodol UltraFluid is a lipophilic contrast medium composed of iodized poppy seed oil that preferentially accumulates in hepatocellular carcinoma and other liver tumors due to their increased vascularity and the Kupffer cell uptake mechanism. It is used both as a diagnostic imaging agent for detecting liver lesions and as a therapeutic embolic agent in transarterial chemoembolization (TACE) procedures, where it delivers chemotherapy directly to tumor vasculature while occluding blood supply.","oneSentence":"Lipiodol UltraFluid is an iodized poppy seed oil contrast agent that accumulates in hepatic lesions and provides both diagnostic imaging and therapeutic embolization.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:52:32.387Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (diagnostic imaging and transarterial chemoembolization)"},{"name":"Diagnostic imaging of liver lesions"}]},"trialDetails":[{"nctId":"NCT05629845","phase":"NA","title":"Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-11-22","conditions":"Hepatocellular Carcinoma, Variceal Bleeding","enrollment":84},{"nctId":"NCT05797870","phase":"PHASE2","title":"Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2)","status":"SUSPENDED","sponsor":"Center Eugene Marquis","startDate":"2024-02-14","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":16},{"nctId":"NCT07480382","phase":"NA","title":"Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC","status":"NOT_YET_RECRUITING","sponsor":"Hong Wu","startDate":"2026-04-01","conditions":"Initially Unresectable Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT07477860","phase":"PHASE1","title":"Achilles Tendinopathy Embolization","status":"NOT_YET_RECRUITING","sponsor":"Joint & Vascular Institute","startDate":"2026-03","conditions":"Achilles Tendinopathy (AT)","enrollment":10},{"nctId":"NCT05672108","phase":"PHASE2","title":"Phase II Trial of Lung Chemoemobolization","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-05-12","conditions":"Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm, Pleural Neoplasm","enrollment":30},{"nctId":"NCT05016245","phase":"PHASE3","title":"MANDARIN (S6371)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2021-09-13","conditions":"Inoperable Hepatocellular Carcinoma","enrollment":92},{"nctId":"NCT07449065","phase":"","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI)","enrollment":324},{"nctId":"NCT07395128","phase":"PHASE1","title":"Lateral Plantar Artery Embolization For Plantar Fasciitis","status":"RECRUITING","sponsor":"Joint & Vascular Institute","startDate":"2025-12-20","conditions":"Plantar Fasciitis, Chronic, Plantar Fasciitis","enrollment":10},{"nctId":"NCT02028949","phase":"PHASE1","title":"Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2012-11-22","conditions":"Unresectable Non-metastatic Hepatocellular Carcinoma, Child A/B7 Cirrhosis","enrollment":15},{"nctId":"NCT06095050","phase":"NA","title":"Embolization Treatment of Chronic Refractory Shoulder Tendinopathy","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-01-16","conditions":"Shoulder Pain, Tendinopathy, Rotator Cuff Tendinitis","enrollment":41},{"nctId":"NCT07380633","phase":"PHASE2","title":"Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-23","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":90},{"nctId":"NCT05842174","phase":"PHASE1, PHASE2","title":"Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-02-01","conditions":"Hepatocellular Carcinoma","enrollment":93},{"nctId":"NCT04459468","phase":"","title":"Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-11-04","conditions":"Hepatocellular Carcinoma","enrollment":17},{"nctId":"NCT03727633","phase":"PHASE2","title":"Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2018-07-19","conditions":"Carcinoma, Hepatocellular","enrollment":53},{"nctId":"NCT02435953","phase":"PHASE3","title":"TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Ming Zhao","startDate":"2015-02","conditions":"Hepatocellular Carcinoma, Chemoembolization, Therapeutic, Ablation Techniques, RFA","enrollment":242},{"nctId":"NCT07295262","phase":"EARLY_PHASE1","title":"NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2026-01-01","conditions":"Liver Cancer, Adult","enrollment":30},{"nctId":"NCT07293468","phase":"PHASE2, PHASE3","title":"Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)","status":"RECRUITING","sponsor":"Tuen Mun Hospital","startDate":"2024-04-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":106},{"nctId":"NCT05171166","phase":"PHASE2, PHASE3","title":"Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.","status":"TERMINATED","sponsor":"Peking University","startDate":"2021-12-24","conditions":"Hepatocellular Carcinoma","enrollment":18},{"nctId":"NCT07281664","phase":"NA","title":"Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2026-01-01","conditions":"Hepatocellular Carcinoma, Transarterial Chemoembolization","enrollment":30},{"nctId":"NCT07230509","phase":"PHASE2","title":"Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate","status":"RECRUITING","sponsor":"Minia University","startDate":"2025-12-01","conditions":"Pancreaticoduodenectomy, Postoperative Pancreatic Fistula, Pancreas Cancer","enrollment":90},{"nctId":"NCT06632717","phase":"PHASE2","title":"Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-09-01","conditions":"Hepatocellular Carcinoma","enrollment":24},{"nctId":"NCT04379973","phase":"PHASE4","title":"Live Birth After Additional Tubal Flushing With Oil-based Contrast Versus no Additional Flushing:","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dafne Balemans","startDate":"2021-05-25","conditions":"Infertility, Female","enrollment":736},{"nctId":"NCT07221695","phase":"NA","title":"Embolization Strategies for Pelvic Venous Disorders: Foam + Glue vs Foam + Coils","status":"ENROLLING_BY_INVITATION","sponsor":"Kafrelsheikh University","startDate":"2025-08-25","conditions":"Pelvic Congestive Syndrome","enrollment":60},{"nctId":"NCT02625389","phase":"PHASE4","title":"A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures","status":"COMPLETED","sponsor":"Guerbet","startDate":"2017-11-29","conditions":"Congenital Hemangioma, Hemangioendothelioma, Angiosarcoma","enrollment":132},{"nctId":"NCT07178093","phase":"NA","title":"Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization","status":"RECRUITING","sponsor":"Taichung Tzu Chi Hospital","startDate":"2023-01-01","conditions":"Hepatocellular Carcinoma, Transarterial Chemoembolization","enrollment":60},{"nctId":"NCT07132541","phase":"PHASE1","title":"Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate)","status":"RECRUITING","sponsor":"Minia University","startDate":"2025-08-25","conditions":"Pancreaticoduodenectomy, Postoperative Pancreatic Fistula, Pancreas Cancer","enrollment":30},{"nctId":"NCT07099274","phase":"PHASE2","title":"Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-08-22","conditions":"HCC","enrollment":29},{"nctId":"NCT07138885","phase":"PHASE2","title":"A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Hepatocellular Carcinoma (HCC), Second Line Treatment","enrollment":62},{"nctId":"NCT07100405","phase":"","title":"TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-08-15","conditions":"Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT06740370","phase":"NA","title":"TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12-13","conditions":"Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody","enrollment":32},{"nctId":"NCT06323382","phase":"","title":"Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-01-01","conditions":"Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab","enrollment":240},{"nctId":"NCT04728633","phase":"PHASE2","title":"Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-09-27","conditions":"Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8","enrollment":28},{"nctId":"NCT06204159","phase":"NA","title":"Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2024-02-01","conditions":"Hepatocellular Carcinoma, Neuroendocrine Tumors","enrollment":12},{"nctId":"NCT04200417","phase":"PHASE1","title":"Chemoembolization for Lung Tumors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-12-13","conditions":"Lung Metastases, Endobronchial Metastases, Pleural Metastases","enrollment":10},{"nctId":"NCT06859164","phase":"PHASE2","title":"Genicular Artery Embolization for Reducing Pain in Medically Refractory Symptomatic Knee Osteoarthritis","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-05-01","conditions":"Knee Osteoarthritis, Knee Osteoarthritis (Knee OA), Knee Osteoarthritis (OA)","enrollment":50},{"nctId":"NCT06844357","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.","status":"RECRUITING","sponsor":"Zhejiang Raygene Pharmaceuticals Co., Ltd","startDate":"2025-03-27","conditions":"HCC","enrollment":300},{"nctId":"NCT06898398","phase":"","title":"TACE Combined Surgery for the Resectable Huge HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-01-01","conditions":"Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer","enrollment":326},{"nctId":"NCT06050200","phase":"NA","title":"TANGO-LIVER Three Arm Nuclear Growth Observation in Liver Surgery","status":"RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2024-08-28","conditions":"Liver Metastases, Liver Cancer, Liver Neoplasms","enrollment":154},{"nctId":"NCT04297280","phase":"PHASE2","title":"TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Fudan University","startDate":"2020-04-29","conditions":"Hepatocellular Carcinoma","enrollment":25},{"nctId":"NCT06848556","phase":"PHASE1, PHASE2","title":"Evaluate the Effect of Tirazamine on Primary Liver Cancer.","status":"TERMINATED","sponsor":"Zhejiang Raygene Pharmaceuticals Co., Ltd","startDate":"2021-05-14","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":16},{"nctId":"NCT06038552","phase":"","title":"Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2002-01-01","conditions":"GIST, Malignant, Liver Metastases","enrollment":238},{"nctId":"NCT06611007","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment","status":"RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2025-01-30","conditions":"Osteoarthritis","enrollment":15},{"nctId":"NCT06805942","phase":"NA","title":"Embolization for the Treatment of Heel Pain Secondary to Plantar Fasciitis","status":"RECRUITING","sponsor":"IR Centers","startDate":"2025-02-15","conditions":"Plantar Fasciitis of Both Feet","enrollment":10},{"nctId":"NCT03705078","phase":"NA","title":"\"Early TIPS\" Versus Glue Obliteration to Prevent Rebleeding From Gastric Varices","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2019-01-03","conditions":"Bleeding Gastric Varices, Cirrhosis","enrollment":104},{"nctId":"NCT06114082","phase":"PHASE2","title":"TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2023-04-28","conditions":"Hepatocellular Carcinoma, Liver Cancer","enrollment":128},{"nctId":"NCT02724540","phase":"PHASE2","title":"Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2016-03","conditions":"Neuroendocrine Tumor, Malignant, Liver Metastases","enrollment":162},{"nctId":"NCT05435014","phase":"PHASE1, PHASE2","title":"T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"T-ACE Medical Co., Ltd","startDate":"2022-09-13","conditions":"Hepatocellular Carcinoma","enrollment":90},{"nctId":"NCT06609850","phase":"NA","title":"The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-01","conditions":"Recurrent Hepatocellular Carcinoma, Lenvatinib, Local Therapy","enrollment":116},{"nctId":"NCT02174549","phase":"PHASE1, PHASE2","title":"Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer","status":"RECRUITING","sponsor":"Teclison Ltd.","startDate":"2014-09","conditions":"Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic, Neuroendocrine Tumors","enrollment":25},{"nctId":"NCT03145558","phase":"PHASE2","title":"TATE Versus TACE in Intermediate Stage HCC","status":"TERMINATED","sponsor":"Teclison Ltd.","startDate":"2017-12-05","conditions":"Carcinoma, Hepatocellular","enrollment":6},{"nctId":"NCT03259867","phase":"PHASE2","title":"Combination of TATE and PD-1 Inhibitor in Liver Cancer","status":"RECRUITING","sponsor":"Teclison Ltd.","startDate":"2017-07-01","conditions":"Hepatocellular Carcinoma, Gastric Cancer","enrollment":54},{"nctId":"NCT03268499","phase":"NA","title":"Emulsion Versus Suspension in Chemoembolization for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2016-09-09","conditions":"Hepatocellular Carcinoma","enrollment":80},{"nctId":"NCT06678308","phase":"NA","title":"Comparison of Glue with Microparticles in Prostatic Artery Embolization","status":"NOT_YET_RECRUITING","sponsor":"Almaviva Sante","startDate":"2024-12-01","conditions":"Benign Prostatic Hyperplasia","enrollment":96},{"nctId":"NCT04954794","phase":"PHASE2","title":"TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2021-07-14","conditions":"Hepatocellular Carcinoma","enrollment":29},{"nctId":"NCT01678664","phase":"PHASE2","title":"Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2012-12","conditions":"Neuroendocrine Tumors, Hepatic Metastases, Metastases","enrollment":74},{"nctId":"NCT06602986","phase":"NA","title":"Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Pak Emirates Military Hospital","startDate":"2024-10-12","conditions":"HCC - Hepatocellular Carcinoma","enrollment":96},{"nctId":"NCT01906216","phase":"PHASE3","title":"Sorafenib Chemoembolization Evaluation Controlled Trial","status":"COMPLETED","sponsor":"Air Force Military Medical University, China","startDate":"2013-09","conditions":"Hepatocellular Carcinoma","enrollment":199},{"nctId":"NCT06563908","phase":"NA","title":"Lipiodol Prior to FET (LIFE)","status":"NOT_YET_RECRUITING","sponsor":"Mỹ Đức Hospital","startDate":"2024-08-10","conditions":"IVF, Frozen Embryo Transfer, Hysterosalpingography","enrollment":784},{"nctId":"NCT04220944","phase":"PHASE1","title":"Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-01-01","conditions":"Hepatic Carcinoma","enrollment":45},{"nctId":"NCT02856126","phase":"PHASE3","title":"HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-08","conditions":"Hepatocellular Carcinoma","enrollment":214},{"nctId":"NCT06485466","phase":"PHASE3","title":"TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Guohui Xu","startDate":"2024-07-01","conditions":"Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab","enrollment":101},{"nctId":"NCT05882188","phase":"NA","title":"The Cost-effectiveness of Hysterosalpingography Versus Hysterosalpingo-foam Sonography During Fertility Work-up","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2023-09-22","conditions":"Infertility","enrollment":1102},{"nctId":"NCT02762266","phase":"PHASE3","title":"Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization","status":"TERMINATED","sponsor":"Stanford University","startDate":"2016-02-27","conditions":"Child-Pugh Class A, Child-Pugh Class B, Recurrent Hepatocellular Carcinoma","enrollment":13},{"nctId":"NCT06262555","phase":"NA","title":"Novel Light Delivery Method for Performing Transbronchial Photodynamic Therapy for Peripheral Lung Cancer","status":"UNKNOWN","sponsor":"Taoyuan General Hospital","startDate":"2024-03","conditions":"Lung Cancer, Lung Cancer Metastatic","enrollment":3},{"nctId":"NCT06245785","phase":"","title":"Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function","status":"COMPLETED","sponsor":"Tang-Du Hospital","startDate":"2023-01-01","conditions":"Hepatic Cancer","enrollment":2200},{"nctId":"NCT06247293","phase":"","title":"Surgical Resection Combined With Intraperitoneal Hyperthermic Chemotherapy","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2024-02-01","conditions":"Hyperthermic Intraperitoneal Chemotherapy, Hepatocellular Carcinoma, Ruptured Liver","enrollment":100},{"nctId":"NCT06245798","phase":"","title":"Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension","status":"COMPLETED","sponsor":"Tang-Du Hospital","startDate":"2023-01-01","conditions":"Hepatic Carcinoma","enrollment":3000},{"nctId":"NCT06199297","phase":"","title":"Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-03-02","conditions":"Hepatocellular Carcinoma","enrollment":188},{"nctId":"NCT05021250","phase":"NA","title":"SBRT With DIBH for HCC After TACE and Lipiodol Marking","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-07-21","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT05490381","phase":"PHASE1","title":"Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes","status":"WITHDRAWN","sponsor":"University of Washington","startDate":"2023-12-21","conditions":"Malignant Neoplasm in the Head and Neck, Metastatic Malignant Neoplasm in the Head and Neck","enrollment":""},{"nctId":"NCT04733092","phase":"PHASE1","title":"Safety and Efficacy of a Lipiodol Emulsion for the Embolization of Hypervascularizations in Patients With Knee Pain (LipioJoint1)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-03-03","conditions":"Knee Osteoarthritis","enrollment":22},{"nctId":"NCT05291338","phase":"","title":"Pharmacogenetic Study in Hepatocellular Carcinoma Patients.","status":"COMPLETED","sponsor":"Rehab Werida","startDate":"2022-01-01","conditions":"Hepatocellular Carcinoma","enrollment":107},{"nctId":"NCT05304572","phase":"","title":"Multi-Detector CT Angiography With 3D Reconstruction Versus Digital Subtraction Angiography","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-05-01","conditions":"Hepatocellular Carcinoma","enrollment":70},{"nctId":"NCT02973685","phase":"PHASE3","title":"HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-10-01","conditions":"HepatoCellular Carcinoma","enrollment":315},{"nctId":"NCT05875558","phase":"NA","title":"M-TACE Treatment for Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-07-01","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT05608590","phase":"PHASE4","title":"What is the Best Moment for Performing an HSG in Women With a Unfulfilled Childwish","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2019-08-22","conditions":"Female Infertility","enrollment":554},{"nctId":"NCT03662841","phase":"NA","title":"Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Chinese University of Hong Kong","startDate":"2018-07-13","conditions":"Carcinoma, Hepatocellular","enrollment":11},{"nctId":"NCT03800940","phase":"NA","title":"Trans-drain Occlusion for Postoperative Pancreatic Fistula- A Double Blind Randomized Clinical Trial","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-01-11","conditions":"Pancreatic Fistula","enrollment":60},{"nctId":"NCT02125396","phase":"PHASE3","title":"Adjuvant Radiotherapy Comparing TACE for Curative HCC","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2019-05-01","conditions":"Hepatocellular Carcinoma","enrollment":150},{"nctId":"NCT05280444","phase":"PHASE2, PHASE3","title":"Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-05-28","conditions":"Hepatocellular Carcinoma","enrollment":216},{"nctId":"NCT05631613","phase":"","title":"Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT04178642","phase":"PHASE2","title":"The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol","status":"WITHDRAWN","sponsor":"University Hospital, Montpellier","startDate":"2020-09-22","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT05647954","phase":"PHASE3","title":"A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver","status":"UNKNOWN","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2022-12-31","conditions":"Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms","enrollment":350},{"nctId":"NCT04780802","phase":"NA","title":"Balloon Assisted Transarterial Therapy for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2022-05-01","conditions":"Hepatocellular Carcinoma","enrollment":10},{"nctId":"NCT04967482","phase":"NA","title":"DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2021-07-09","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":216},{"nctId":"NCT05535998","phase":"","title":"TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT","status":"COMPLETED","sponsor":"Yunfei Yuan","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma","enrollment":743},{"nctId":"NCT05472896","phase":"PHASE3","title":"TACE With Dicycloplatin(TP21) in Unresectable HCC","status":"UNKNOWN","sponsor":"Gao-jun Teng","startDate":"2022-06-09","conditions":"Hepatocellular Carcinoma","enrollment":332},{"nctId":"NCT05361161","phase":"PHASE2","title":"Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC)","status":"UNKNOWN","sponsor":"Gang Wu","startDate":"2022-06-01","conditions":"Gastric Cancer, Embolization","enrollment":60},{"nctId":"NCT03604549","phase":"PHASE4","title":"Sonographic Hysterosalpingography: Oil vs Water Based Media (SHOW Trial)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2019-01-11","conditions":"Infertility","enrollment":58},{"nctId":"NCT05340231","phase":"PHASE2","title":"An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC)","status":"UNKNOWN","sponsor":"Gang Wu","startDate":"2022-05-01","conditions":"Colorectal Cancer","enrollment":100},{"nctId":"NCT03259581","phase":"PHASE1","title":"Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2018-01-02","conditions":"Hepatocellular Carcinoma, Bilirubinemia","enrollment":5},{"nctId":"NCT01512407","phase":"NA","title":"RCT on Adjuvant TACE After Hepatectomy for HCC","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2011-11","conditions":"Hepatocellular Carcinoma","enrollment":58},{"nctId":"NCT03322280","phase":"NA","title":"TACE Combined With Iodine-125 Seeds Implantation for HCC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2018-07-01","conditions":"Hepatocellular Carcinoma, Portal Vein Occlusion, Tumor Thrombus","enrollment":270},{"nctId":"NCT05247996","phase":"NA","title":"TACE Combined With \"Target Immune\" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2022-03-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":98},{"nctId":"NCT05233358","phase":"NA","title":"HAIC Combined With Second-line \"Target Immunity\" for HCC With TACE Standard Treatment Low Response or Failure","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2022-02-01","conditions":"Hepatocellular Carcinoma","enrollment":176},{"nctId":"NCT03338647","phase":"PHASE3","title":"SBRT or TACE for Advanced HCC","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2017-10-26","conditions":"Hepatocellular Carcinoma","enrollment":180},{"nctId":"NCT01387932","phase":"PHASE3","title":"HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer","status":"TERMINATED","sponsor":"Merit Medical Systems, Inc.","startDate":"2011-06","conditions":"Hepatocellular Carcinoma","enrollment":235},{"nctId":"NCT05017922","phase":"NA","title":"Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2017-01-01","conditions":"Hepatocellular Carcinoma, Esophagogastric Varices","enrollment":89},{"nctId":"NCT04490694","phase":"PHASE2","title":"TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-03-01","conditions":"Hepatocellular Carcinoma","enrollment":54},{"nctId":"NCT05053386","phase":"NA","title":"Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-10","conditions":"Hepatocellular Carcinoma","enrollment":186}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oil-based contrast"],"phase":"marketed","status":"active","brandName":"Lipiodol UltraFluid","genericName":"Lipiodol UltraFluid","companyName":"Amsterdam UMC, location VUmc","companyId":"amsterdam-umc-location-vumc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lipiodol UltraFluid is an iodized poppy seed oil contrast agent that accumulates in hepatic lesions and provides both diagnostic imaging and therapeutic embolization. Used for Hepatocellular carcinoma (diagnostic imaging and transarterial chemoembolization), Diagnostic imaging of liver lesions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}